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Background. Intermittent preventive treatment (IPT) in schoolchildren offers a promising option for malaria
control. However, the optimal drug and dosing regimens for IPT remain to be determined.
Methods. We conducted a randomized, double-blind, placebo-controlled trial in 740 schoolchildren aged 6–14
years living in a setting of high malaria transmission in Uganda. Enrolled children were randomized to dihydroar-
temisinin-piperaquine (DP) given once a month (IPTm), DP given once a school term (4 treatments over 12 months,
IPTst), or placebo and followed for 12 months. The primary outcome was the incidence of malaria over 12 months.
Secondary outcomes included parasite prevalence and anemia over 12 months. Analyses were conducted on an in-
tention-to-treat basis.
Results. In the placebo arm, the incidence of malaria was 0.34 episodes per person-year and the prevalence of
parasitemia and anemia was 38% and 20%, respectively. IPTm reduced the incidence of malaria by 96% (95% con-
ﬁdence interval [CI], 88%–99%, P < .0001), the prevalence of asymptomatic parasitemia by 94% (95% CI, 92%–96%,
P < .0001), and the prevalence of anemia by 40% (95% CI, 19%–56%, P < .0001). IPTst had no signiﬁcant effect on
the incidence of symptomatic malaria or the prevalence of anemia, but reduced the prevalence of asymptomatic par-
asitemia by 54% (95% CI, 47%–60%, P < .0001).
Conclusions. Monthly IPT with DP offered remarkable protection against clinical malaria, parasitemia, and ane-
mia in schoolchildren living in a high-malaria-transmission setting.
Clinical Trials Registration. NCT01231880.
Keywords. malaria; intermittent preventive treatment; schoolchildren.
Children of school age (5–14 years) beneﬁt relatively lit-
tle from current malaria control interventions, due to a
focus on younger children and pregnant women [1, 2].
Yet, in Africa, 20%–50% of school-aged children expe-
rience malarial episodes each year [3], with a negative
impact on school attendance and educational perfor-
mance [4, 5]. In high-transmission settings, up to 70%
of school-aged children harbor malaria parasites, caus-
ing anemia [6], cognitive impairment [7, 8], and main-
tenance of reservoirs that promote transmission to
others. Clearly, malaria control would be a valuable ad-
dition to school health programs.
One intervention under investigation is intermittent
preventive treatment (IPT), the administration of
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curative doses of antimalarials at predeﬁned intervals regardless
of infection status. IPT targeted at schoolchildren has resulted
in reduced rates of malaria, asymptomatic parasitemia, and ane-
mia, as well as improved cognitive function [9–13].However, the
optimal drug and dosing regimen are uncertain. We previously
showed that, in a region of high malaria transmission, a single
3-day course of dihydroartemisinin-piperaquine (DP) better
prevented malarial parasitemia over 42 days and was better tol-
erated than either sulfadoxine-pyrimethamine (SP) or amodia-
quine plus sulfadoxine-pyrimethamine (AQ + SP) [14]. We
herein report results of a trial evaluating DP, either monthly
(IPTm) or once per school term (IPTst), in schoolchildren in
a high-malaria-transmission setting in Uganda.
METHODS
Study Design, Setting, and Population
This randomized, double-blind, placebo-controlled trial was
conducted between February 2011 and February 2012 in Mu-
landa Primary School, Tororo District, in eastern Uganda. Tor-
oro District is characterized by high-intensity year-round
malaria transmission, principally of Plasmodium falciparum,
with an estimated entomological inoculation rate of 562 infec-
tive bites per person per year [15]. In the 5 years prior to this
study, malaria control in Tororo District was typically limited to
the promotion of IPT during pregnancy, distribution of insec-
ticide-treated nets (ITNs) through antenatal care services, and
malaria case management with artemisinin-based combination
therapy. In January 2011, a community-based mass campaign
to distribute free ITNs was conducted.
Mulanda subcounty has 8 primary schools. Mulanda Prima-
ry School was selected due to its large population (1320 stu-
dents) and close proximity (approximately 500 m) to the
main public health facility, Mulanda Health Centre IV. Meet-
ings were held to explain the nature and purpose of the trial
to teachers and parents or guardians, and written informed
consent was obtained. All children with consent from their par-
ent/guardian were screened for eligibility. Children were exclud-
ed if they had (i) known allergy or adverse reaction to
artemisinin-based regimens; (ii) history of menarche; (iii)
fever (axillary temperature ≥37.5°C) or history of fever in the
previous 24 hours; (iv) evidence of severe malaria or danger
signs; or (v) ongoing antimalarial treatment. Recruitment was
done once and closed after baseline assessments.
Enrollment Procedures
At enrollment, a standardized questionnaire was administered
to children fulﬁlling selection criteria to obtain data on sociode-
mographics and bed-net ownership and use. A standardized as-
sessment of symptoms and a focused physical examination
including measurement of weight and temperature were
conducted. A ﬁnger-prick blood sample was obtained to assess
for Plasmodium infection by thick and thin blood smear and for
hemoglobin estimation. A stool sample was collected to assess
for helminth infection. All children received a long-lasting ITN,
and a single dose of albendazole (400 mg) was administered.
Study Drugs and Treatment Allocation
A randomization list was computer-generated using ﬁxed
blocks of 12 by an individual not involved in patient care. Par-
ticipants were randomized using previously prepared, consecu-
tively numbered, opaque sealed envelopes and assigned study
numbers sequentially. A nurse not involved in care allocated
the study group after opening the correspondingly numbered
envelope. All other study personnel were blinded to study
group assignments, and children were not informed of their
regimen, but the color and taste of study medication and
placebo were dissimilar. Study drugs were dosed as DP (Duo-
Cotecxin, Holley-Cotec Pharmaceuticals, Beijing, China) once
daily for 3 consecutive days each month (IPTm), or at the be-
ginning of each school term (February 2011, May 2011, August
2011, and January 2012 [IPTst]). DP was dosed using weight-
based guidelines targeting a total dose of 6.4 mg/kg dihydroar-
temisinin and 51.2 mg/kg piperaquine, given with glucose
biscuits. Placebo was administered to the placebo and IPTst
groups to simulate the IPTm dosing schedule. All treatment
was administered at school by the study nurses and was directly
observed. After drug administration, children were observed for
30 minutes, and treatment was readministered if vomiting
occurred.
Follow-up Visits
Finger-prick blood smears were performed monthly to assess
for Plasmodium infection. At the start of each school term, stan-
dardized history and physical examination and assessments for
hemoglobin were performed prior to treatment. Children ab-
sent for any scheduled visits were followed up at home. School
attendance was assessed daily by roll call by teachers, with ab-
sent children followed up at home by study personnel to estab-
lish reasons for absenteeism. Children who were absent due to
illness were taken to the study clinic for diagnosis, management,
and documentation. Adverse events were assessed and graded
according to standardized criteria. Children with illnesses
other than malaria received standard of care or were referred
to Mulanda Health Centre. Medications with antimalarial activ-
ity were avoided whenever possible.
Recording of Clinical Malaria Episodes
Monitoring for malaria was by active case detection. Sick chil-
dren were identiﬁed by teachers and sent to the study clinic and
absent children were visited at home and taken to the study
clinic if ill. The clinic was open 7 days a week. Children with
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documented fever (axillary temperature ≥37.5°C) or history of
fever in the previous 24 hours had a blood sample for thick and
thin smears. Malaria was deﬁned as fever (documented or by
history) with any quantity of malaria parasites on the blood
smear. Episodes of uncomplicated malaria were treated with ar-
temether-lumefantrine, the recommended ﬁrst-line treatment
in Uganda, following standard dosing guidelines and under
supervision of the study nurse. Treatment failures within 14
days of prior therapy were treated with oral quinine 10 mg/kg
every 8 hours for 7 days. Episodes of complicated malaria (se-
vere malaria or danger signs) were referred to Mulanda Health
Centre IV for intravenous quinine.
Laboratory Evaluations
Blood smears were labeled, air dried, and stained with 2% Gi-
emsa for 30 minutes. Parasite densities were determined from
thick blood smears by counting asexual parasites per 200
white blood cells (or per 500 white blood cells if the count
was <10 parasites per 200 cells), assuming a white blood cell
count of 8000 cells/mL. A smear was considered negative if
no parasites were seen in 100 high-powered ﬁelds. Gametocyte-
mia was determined using the same methodology. Thin smears
were viewed for species identiﬁcation. Two independent and
experienced microscopists read the slides, with a third micros-
copist resolving discrepancies. Stool examination was by the
Kato-Katz technique to assess for helminth infections. Hemo-
globin concentration was assessed using a portable hemoglobin-
ometer (HemoCue Ltd, Angelholm, Sweden) and estimated to
0.1 g/dL. Follow-up for malaria, anemia, and parasitemia were
conducted for 12 months after enrollment. Participants were
withdrawn for change of school, withdrawal of informed con-
sent, or noncompliance with study procedures.
Statistical Analysis
The study was designed to test the hypothesis that IPTm would
reduce the incidence of malaria compared with placebo by 33%
or greater. We assumed that the incidence of malaria would be
0.57 episodes per person year in the placebo arm [14], and thus
we would need to enroll 228 participants in each arm to detect
our targeted protective efﬁcacy with 80% power at 95% signiﬁ-
cance, allowing for 10% loss to follow-up.
Data were double-entered and cross-checked in a bespoke
Microsoft Access database (Microsoft Corp, Seattle, Washing-
ton). Consistency checks were performed and all discrepancies
and queries veriﬁed against original paper forms. Statistical
analyses were done using Stata version 12.0 software (StataCorp,
College Station, Texas). All analyses used an intention-to-treat
approach. Incidence outcomes were compared using a negative
binomial regression model, and prevalence outcomes were
compared using generalized estimating equations with adjust-
ment for repeated measures in the same study participant. Mea-
sures of association were expressed as incidence rate ratios,
prevalence ratios, and mean differences. A P value ≤.05 was
considered statistically signiﬁcant. The primary outcome was
the incidence of malaria, deﬁned as the number of incident ep-
isodes per time at risk. Time at risk was calculated from the day
Figure 1. Trial proﬁle. Abbreviations: F/up, follow-up; IPTm, intermittent preventive treatment once a month; IPTst, intermittent preventive treatment once
a school term.
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following the initiation of study drugs to the last day of obser-
vation, minus 14 days after each episode of malaria, a standard
approach. Malaria within 1 month of IPTst was deﬁned as any
episode in March, June, or September, within 2 months as any
episode in April, July, or October, within 3 months as any ep-
isode in May, August, or November, and within 4 months as
any episode in December.
Secondary outcomes included prevalence of parasitemia, de-
ﬁned as the number of positive smears divided by the total
number of smears over 1 year. Parasitemia after IPTst was de-
ﬁned as described above for malaria. Anemia was deﬁned as
<11.5 g/dL for children aged 6–11 years and <12.0 g/dL for
those aged 12–14 years [16].
An adverse event was deﬁned as any untoward medical occur-
rence, irrespective of its suspected relationship to study medica-
tions. All events were graded by severity and relationship to study
treatment [17]. The risk of experiencing an adverse event was es-
timated, and comparisons with placebo were made using χ2 tests.
Role of the Funding Source and Ethical Approval
The sponsors had no role in study design, data collection, data
analysis, data interpretation, or writing the report. The corre-
sponding author had full access to study data and ﬁnal respon-
sibility for submission of the manuscript. Ethical approval was
obtained from the Uganda National Council for Science and
Technology and the Makerere University School of Medicine
Research and Ethics Committee.
RESULTS
Study Subjects and Follow-up
Between January and February 2011, 826 children were
screened for eligibility, and 740 (89.6%) met inclusion criteria
and were randomized to study arms (Figure 1). Baseline char-
acteristics of participants were similar across the study arms
(Table 1). A total of 713 (96.4%) children completed 1 year of
follow-up. Among the children lost during follow-up, 20
changed schools, 3 withdrew (1 hypersensitivity reaction after
the ﬁrst course of treatment, 1 pregnancy, and 1 withdrawal
of consent), 3 dropped out of school, and 1 died (Figure 1).
Efﬁcacy Outcomes Following IPT
There were 167 incident episodes of malaria over 12 months of
follow-up (Table 2). The incidence of malaria was signiﬁcantly
lower in the IPTm arm compared with the placebo arm (0.01 vs
0.34 episodes per person per year, respectively), resulting in a
96% protective efﬁcacy (incidence rate ratio [IRR], 0.04; 95%
conﬁdence interval [CI], .01–.12; P < .0001). Compared with
the placebo arm, the overall incidence of malaria (Table 2) or
the cumulative risk of developing at least 1 episode of malaria
(Figure 2) over 1 year of follow-up was not signiﬁcantly
different in the IPTst arm. However, compared with the placebo
arm, the incidence of malaria was signiﬁcantly lower within the
ﬁrst and second months after IPTst administration, resulting in
66% (IRR, 0.34; 95% CI, .19–.59; P < .0001) and 45% (IRR, 0.55;
95% CI, .30–.99; P = .037) protective efﬁcacies within 1 and 2
months of IPTst administration, respectively. Restricting the
case deﬁnition of malaria to fever and >2000 parasites/µL of
blood yielded similar results and comparisons (Table 2).
The prevalence of parasitemia, which was assessed monthly,
was signiﬁcantly lower in the IPTm (2%) and IPTst (18%) arms
compared with the placebo (38%) arm, resulting in a 94% pro-
tective efﬁcacy with IPTm (prevalence ratio [PR], 0.06; 95% CI,
.40–.08; P < .001) and 54% protective efﬁcacy with IPTst (PR,
0.46; 95% CI, .40–.53; P < .001) over 1 year of follow-up. Similar
to what was observed with malarial incidence, the prevalence of
parasitemia in the IPTst group increased with increasing
Table 1. Baseline Characteristics of the Study Population by
Treatment Group
Characteristic
Study Group
Placebo IPTst IPTm
No. of children 248 248 244
Sex, female, No. (%) 129 (52.0) 139 (56.1) 126 (51.6)
Age at enrollment, y,
mean (SD)
9.8 (2.3) 9.7 (2.2) 9.9 (2.1)
Weight, kg, mean (SD) 28.6 (8.4) 28.4 (8.2) 28.6 (8.2)
Hemoglobin, g/dL, mean
(SD)
11.7 (1.0) 11.7 (1.1) 11.6 (1.0)
Household owning at
least 1 bed-net, No. (%)
224 (90.3) 218 (87.9) 220 (90.2)
Bed-net use in last 24 h,
No. (%)
91 (36.7) 87 (35.1) 84 (34.4)
Asymptomatic parasitemia
All Plasmodium
species, No. (%)
79 (31.9) 73 (29.4) 71 (29.1)
P. falciparum 70 70 64
P. malariae 5 1 5
P. vivax 2 0 2
P. ovale 2 2 0
Geometric mean parasite
density per µL
549 647 611
Gametocyte presence,
No. (%)
9 (3.6) 6 (2.4) 7 (2.9)
Helminths present, No.
(%)
21 (8.5) 13 (5.2) 22 (9.0)
Socioeconomic group, quartiles, No., (%)
Poorest 67 (27.0) 62 (25.0) 67 (27.5)
Poor 85 (34.3) 82 (33.1) 74 (30.3)
Less poor 41 (16.5) 36 (14.5) 43 (17.6)
Least poor 55 (22.2) 68 (27.4) 60 (24.6)
Abbreviations: IPTm, intermittent preventive treatment once a month; IPTst,
intermittent preventive treatment once a school term; SD, standard deviation.
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Table 2. Clinical, Parasitological, and Hematological Outcomes by Treatment Group After 1 Year of Follow-up
Outcome
Study Group
Placebo IPTst IPTm
Events PYAR Incidence Events PYAR Incidence
IRR IPTst vs
Placebo (95% CI) Events PYAR Incidence
IRR IPTm vs
Placebo (95% CI)
Clinical malaria
All episodes 83 242.7 0.34 81 238.1 0.34 1.00 (.68–1.47) 3 240.5 0.01 0.04 (.01–.12)
Parasite density >2000/µL 49 242.7 0.20 63 238.1 0.26 1.32 (.82–2.14) 1 240.5 0.004 0.02 (.003–.15)
Episodes within 1 mo of IPTsta 38 94.8 0.40 12 93.5 0.13 0.31 (.15–.63) 0 94.3 0.00 0
Episodes within 2 mo of IPTsta 22 56.5 0.39 14 56.5 0.25 0.62 (.29–1.32) 0 56.4 0.00 0
Episodes within 3 mo of IPTsta 21 57.1 0.37 38 55.4 0.69 1.96 (1.06–3.62) 2 56.4 0.04 0.09 (.02–.42)
Episodes within 4 mo of IPTsta 2 34.2 0.06 17 32.8 0.52 9.37 (2.09–42.1) 1 33.5 0.03 0.51 (.05–5.72)
Outcome Events Total Tests Prevalence Events Total Tests Prevalence
Prevalence Ratio
IPTst vs Placebo
(95% CI) Events Total Tests Prevalence
Prevalence Ratio
IPTm vs Placebo
(95% CI)
Parasitemia
All events 1037 2700 0.38 472 2644 0.18 0.46 (.40–.53) 58 2638 0.02 0.06 (.04–.08)
Events within 1 mo of IPTsta 326 981 0.33 23 960 0.02 0.07 (.05–.11) 19 960 0.02 0.06 (.04–.10)
Events within 2 mo of IPTsta 297 738 0.40 126 726 0.17 0.43 (.35–.53) 14 721 0.02 0.05 (.03–.09)
Events within 3 mo of IPTsta 307 737 0.42 238 720 0.33 0.79 (.69–.92) 20 719 0.03 0.06 (.04–.11)
Events within 4 mo of IPTsta 107 244 0.44 85 238 0.36 0.81 (.65–1.02) 5 238 0.02 0.05 (.02–.12)
Anemia
All events 148 736 0.20 125 716 0.17 0.86 (.66–1.13) 87 717 0.12 0.60 (.44–.81)
Gametocytemia
All events 129 2700 0.05 54 2644 0.02 0.43 (.31–.58) 11 2638 0.004 0.09 (.05–.16)
Abbreviations: CI, confidence interval; IPTm, intermittent preventive treatment once a month; IPTst, intermittent preventive treatment once a school term; IRR, incidence rate ratio; PYAR, person year at risk.
a IPTst was administered in February, May, and August 2011 as well as January 2012. Events within 1 month of IPTst occurred in March, June, and September 2011. Events within 2 months of IPTst occurred in April,
July, and October 2011. Events within 3 months of IPTst occurred in May, August, and November 2011. Events within 4 months of IPTst occurred in December 2011.
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duration after treatment. The prevalence of gametocytemia was
signiﬁcantly lower in the IPTm and IPTst groups compared
with the placebo group (Table 2).
Mean hemoglobin increased between baseline and 1 year
in all children. The mean increase in hemoglobin in the IPTst
group did not differ from that in the placebo group (0.86 g/dL
[interquartile range {IQR}, −0.1 to 1.8] vs 0.79 g/dL [IQR, −0.1
to 1.7]; P = .638). In contrast, the mean increase in hemoglobin
in children in the IPTm group was signiﬁcantly greater than
that in the placebo group (1.20 g/dL [IQR, 0.1–2.15] vs 0.79
g/dL IQR −0.1 to 1.7; P = .003). The overall prevalence of ane-
mia was signiﬁcantly lower in the IPTm arm (0.12) but not the
IPTst arm (0.17), compared with the placebo arm (0.20), result-
ing in a 40% protective efﬁcacy for IPTm (PR, 0.60; 95% CI,
.44–.81; P = .030) (Table 2). Only 2 children had hemoglobin
levels <8 g/dL during the 1-year follow-up period. One child,
diagnosed with acute lymphoblastic leukemia, had severe ane-
mia (hemoglobin level, 3.4 g/dL).
Safety Outcomes
There was 1 death, due to acute lymphoblastic leukemia, in a 7-
year-old randomized to IPTst. Fourteen serious adverse events
were reported, 6 in the IPTm group, 5 in the IPTst group, and 3
in the placebo group. All serious adverse events were judged
unlikely to be associated with treatment; the most commonly
reported events were fractures. Mild events, such as fever, head-
ache, nausea, vomiting, and diarrhea, which were commonly
associated with malaria, were more frequent in the placebo
group than the intervention arms (Table 3).
DISCUSSION
School-aged children suffer consequences of malaria but are
generally neglected in malaria control strategies. One control
strategy under investigation for schoolchildren is IPT. We pre-
viously showed that, in Ugandan schoolchildren, a single course
of DP was more efﬁcacious than either SP or AQ + SP in pre-
venting parasitemia over the subsequent 6 weeks [14]. In this
study, we compared 2 DP dosing regimens and placebo in the
same high-malaria-transmission setting. IPTm was highly efﬁ-
cacious, reducing the incidence of malaria by 96%, the preva-
lence of parasitemia by 94%, and the prevalence of anemia by
40%. IPTst only provided protection against malaria within the
ﬁrst 2 months after drug administration and against parasitemia
within the ﬁrst 3 months after drug administration. Our results
suggest that DP administered at monthly intervals, but not
dosed once a term, is a remarkably effective measure for
the prevention of malaria in schoolchildren living in a high-
transmission setting.
For IPT, a drug should eliminate circulating parasites and
persist at sufﬁcient levels to prevent multiplication of parasites
acquired between doses. In our study, IPTm was highly efﬁca-
cious in reducing parasitemia and preventing malaria. These
ﬁndings are consistent with the long half-life of piperaquine
Figure 2. Cumulative risk of malaria over 1 year of follow-up by treatment group. Abbreviations: IPTm, intermittent preventive treatment once a month;
IPTst, intermittent preventive treatment once a school term.
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[18]. Previous studies have shown that DP is highly efﬁcacious
for the treatment of malaria, with substantial posttreatment
prophylactic efﬁcacy in Africa [19, 20] and Asia [21]. In one
study that considered less-frequent preventive dosing, monthly
DP was more efﬁcacious than a bimonthly regimen in prevent-
ing malaria in adults in Thailand [22]. Similarly, in our study,
IPTm was more efﬁcacious than IPTst. Taken together, avail-
able results suggest that a monthly dosing interval is most ap-
propriate for IPT with DP [18, 22].
IPTm signiﬁcantly improved hemoglobin levels and reduced
the risk of anemia, probably due to effects against malaria. IPTst
had no effect on anemia, in contrast to a previous study in
Kenya, where the protective efﬁcacy of IPTst with AQ + SP
against anemia was 48% [9]. In the Kenyan study, parasite prev-
alence was 4.6% in children receiving IPTst, compared with
17.8% in our study. The explanation for differential impacts
on parasitemia and anemia in the 2 studies may be differences
in transmission intensities, the drugs used for IPT, or the socio-
economic status of study participants.
IPT with SP is recommended in pregnancy (IPTp) and in in-
fants (IPTi) living in areas with moderate to high malaria trans-
mission, whereas seasonal malaria chemoprevention (SMC) with
monthly AQ + SP is recommended in children aged <5 years liv-
ing in areas with highly seasonal malaria transmission in the
Sahel subregion of Africa [23]. Although studies have demon-
strated beneﬁts of IPT and SMC with SP-containing regimens
[9, 24, 25], widespread resistance to SP in Africa [26] may render
these malaria control measures ineffective [14, 27].DP may serve
as a suitable alternative, especially for SMC, for which issues of
tolerability to AQ+ SP have also been raised [14]. However, be-
fore implementation, the efﬁcacy, tolerability, and safety of DP
for IPTp, IPTi, and SMC should be further evaluated.
Our results suggest that monthly administration of DP will
have major beneﬁts for schoolchildren living in areas with
high malaria endemicity. However, some concerns regarding
this approach need to be addressed. First, the feasibility of
monthly administration of a 3-day treatment regimen may be
questioned, but it is noteworthy that schools offer relatively
Table 3. Risk of Adverse Events in All Participants Over 1 Year of Follow-up by Treatment Group, and Pairwise ComparisonsWith Placebo
Event Description
Study Group
Placebo (n = 248) IPTst (n = 248) IPTm (n = 244)
% Risk (95% CI) % Risk (95% CI) P Valuea % Risk (95% CI) P Valuea
Any adverse event 92.7 (88.8–95.4) 90.7 (86.5–93.7) .420 88.9 (84.4–92.3) .145
AEs commonly related to DP
Anorexia 1.2 (.4–3.5) 1.2 (.4–3.5) 1.000 1.6 (.6–4.1) .706
Nausea 5.7 (3.4–9.3) 3.2 (1.6–6.2) .193 0.8 (.2–2.9) .003
Vomiting 11.3 (7.9–15.8) 9.7 (6.6–14.0) .561 3.7 (2.0–6.9) .001
Diarrhea 15.7 (11.7–20.7) 6.9 (4.3–10.7) .006 8.2 (5.4–12.3) .028
Pruritus 0.8 (.2–2.9) 1.2 (.4–3.5) .654 0.8 (.2–2.9) 1.000
Commonest AEs reported
Cough 72.9 (67.1–78.1) 66.5 (60.5–72.1) .121 70.1 (64.1–75.5) .491
Headache 55.7 (49.4–61.7) 50.0 (43.8–56.2) .212 38.5 (32.6–44.8) <.001
Fever 44.7 (38.7–50.9) 38.3 (32.5–44.5) .205 25.0 (19.9–30.8) <.001
Abdominal pain 29.8 (24.5–35.8) 29.0 (23.7–34.9) .845 22.5 (17.8–28.2) .066
Flu 33.9 (28.3–39.9) 29.0 (23.7–34.9) .240 39.8 (33.8–46.0) .175
Wounds 18.6 (14.2–23.9) 18.6 (14.2–23.8) .977 17.6 (13.4–22.9) .795
Skin rash 10.9 (7.6–15.4) 12.5 (8.9–17.2) .579 11.1 (7.7–15.6) .943
Joint aches 9.3 (6.3–13.5) 10.1 (6.9–14.5) .763 7.8 (5.0–11.8) .552
Sore throat 10.9 (7.6–15.4) 8.9 (5.9–13.1) .456 8.6 (5.7–12.8) .390
Weakness 8.8 (5.3–12.1) 4.8 (2.8–8.3) .077 4.9 (2.8–8.4) .087
Serious adverse events
All SAEs 1.2 (.4–3.5) 2.0 (.8–4.6) .478 2.5 (1.1–5.3) .284
Fractures 0.4 (.07–2.3) 1.2 (.4–3.5) .317 2.5 (1.1–5.3) .051
Death 0 0.4 (.07–2.3) .319 0
Pneumonia 0.8 (.2–2.9) 0.4 (.07–2.3) .564 0 .158
Abbreviations: AE, adverse event; CI, confidence interval; DP, dihydroartemisinin-piperaquine; IPTm, intermittent preventive treatment once a month; IPTst,
intermittent preventive treatment once a school term; SAE, severe adverse event.
a Reference group is placebo.
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simple settings for administration of directly observed therapies.
Second, prevention of malaria through chemoprevention may
impede the development of immunity, leading to rebound mor-
bidity after completion of the intervention, although rebound
after chemoprevention has generally either not been seen, or
been modest [28], and it would likely be of less importance in
schoolchildren than younger children. Third, chemoprevention
with DP may select for parasites resistant to the components of
the regimen, particularly piperaquine. Older studies reported
resistance to piperaquine in China following years of heavy
use [29]. Analysis of samples from a cohort study in Uganda
[30], but not studies in Burkina Faso [31], showed selection
after treatment with DP toward parasites with pfmdr1 muta-
tions associated with decreased sensitivity to other aminoquino-
lines. The impact of chemoprevention with DP on the selection
of drug-resistant parasites is unknown. Surveillance of parasites
emerging under DP-selective pressure is indicated, and analysis
of samples from our trial is planned. Fourth, these ﬁndings may
not be generalizable to medium- and low-transmission settings.
Fifth, the lack of similarity between the placebo and DP may
have unblinded study participants, but our outcome measures
included clinical and laboratory evaluations by study personnel
blinded to the participants’ study arms. Considering our results
in light of these concerns, further study of the feasibility, safety,
and cost-effectiveness of IPT targeted at schoolchildren with DP
in different transmission settings will be warranted, but none-
theless, implementation of this highly efﬁcacious intervention
in the near future is worthy of strong consideration.
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